핵의학 기업 Curium, 일본의 전립선암 테라노스틱 분야 공동 개발 위해 PeptiDream과 전략적 파트너십 체결
October 02, 2024 11:01 ET
|
Curium US LLC
177Lu-PSMA-I&T 및 64Cu-PSMA-I&T 의 일본 내 임상 개발, 규제 신청 및 상용화 추진 과정에서의 협력 포함양사 간 오랜 기간 형성된 관계를 바탕으로 파트너십 구축일본의 전립선암 신규 진단건수 매년 약 9만 건 수준 파리, Oct. 03, 2024 (GLOBE NEWSWIRE) -- 핵의학 부문을 선도하는...
Curium 宣布與 PeptiDream 建立策略夥伴關係，在日本前列腺癌治療學領域展開合作
October 02, 2024 11:01 ET
|
Curium US LLC
合作內容包括 177Lu-PSMA-I&T 和 64Cu-PSMA-I&T 在日本的臨床開發、監管備案和商業化工作基於兩間公司的長期合作關係日本每年有大約 9 萬宗前列腺癌新病例確診 巴黎, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Curium 是一家世界領先的核醫學企業，今天宣布與 PeptiDream 的全資子公司...
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
October 01, 2024 07:45 ET
|
Curium
Curium partners with PeptiDream for clinical development, regulatory filing, and commercialization of prostate cancer therapies in Japan.
Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide
September 24, 2024 08:45 ET
|
Curium
Curium opens new Netherlands facility for Lu-177 production, ensuring a steady supply of this breakthrough cancer therapy isotope for over 100,000 patients
Curium Anuncia Que PYLCLARI®, un Innovador Trazador PET 18F-PSMA Indicado en Pacientes Con Cáncer De Próstata, Ya Está Disponible en España
September 10, 2024 04:30 ET
|
Curium US LLC
PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, líder mundial en medicina nuclear, ha anunciado hoy que PYLCLARI ® ya está disponible en España para pacientes con cáncer de próstata. PYLCLARI®...
Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain
September 10, 2024 04:30 ET
|
Curium
CURIUM ANNOUNCES PYLCLARI® – AN INNOVATIVE 18F-PSMA PET TRACER INDICATED IN PATIENTS WITH PROSTATE CANCER – IS NOW AVAILABLE IN SPAIN
Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection
July 09, 2024 09:47 ET
|
Curium
Curium advances cancer care with its 505(b)(2) NDA submission to the FDA for Lutetium Lu 177 Dotatate Injection in GEP-NETS patients.
Curium gibt erste kommerzielle Dosen von PYLCLARI® - 18F-PSMA PET radiopharmazeutikum in Österreich bekannt
June 17, 2024 08:51 ET
|
Curium
Erste Dosen von PYLCLARI® werden Anfang Mai 2024 in Österreich verabreichtPYLCLARI® jetzt auch in Frankreich, Deutschland, Griechenland, Italien und den Niederlanden erhältlich PARIS, June 17, 2024 ...
Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer
June 17, 2024 08:51 ET
|
Curium
First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a...
Curium Adds the Institut Laue-Langevin Reactor to Global Irradiation Portfolio to Ensure Continuous Supply of Lutetium-177 to Benefit More Than 100,000 Cancer Patients Over the Next 5 Years
June 05, 2024 05:27 ET
|
Curium
Curium partners with Institut Laue–Langevin to enhance Lutetium-177 supply, benefiting over 100,000 cancer patients in five years.